DVAX logo Dynavax Technologies : DVAX

DVAX

Stock Data

$15.50

Change up

$0.00 (0.00%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

Dynavax Technologies Corp is a biopharmaceutical company based in Emeryville, California, specializing in the development and commercialization of vaccines. Its flagship product is HEPLISAV-B, a hepatitis B vaccine designed for adults, which is available in the United States and Europe. The company also produces CpG 1018, a key ingredient in HEPLISAV-B. Dynavax collaborates with several global partners to expand its vaccine offerings and improve public health outcomes.

All Dynavax Technologies Articles

41 Articles

1 2 3

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.